Pulmonary Surfactant Market, By Type, By Drug Type, By Indications, By Route of Administration, By Distribution Channel, By Geography

Description

Pulmonary Surfactant Market is estimated to be valued at USD 723.2 Mn in 2026 and is expected to reach USD 947.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 723.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.20%	2033 Value Projection:	USD 947.8 Mn

Pulmonary surfactant is a complex and highly surface active material composed of lipids and proteins which is found in the fluid lining the alveolar surface of the lungs. Surfactant plays a vital role in pulmonary physiology. It's major biophysical functions is to prevent alveolar collapse at low lung volume and to preserve bronchiolar patency during normal and forced respiration, and it's major non biophysical, immunological, functions is protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms. Pulmonary surfactant is heterogeneous with respect to biochemical composition, morphological organization and specific biophysical functions. Surfactant prevents alveolar collapse at low lung volume, and preserves

bronchiolar patency during normal and forced respiration (biophysical functions). In addition, it is involved in the protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms (immunological, non-biophysical functions). Pulmonary surfactant can only be harvested by lavage procedures, which may disrupt its pre-existing biophysical and biochemical micro-organization. These limitations must always be considered when interpreting ex vivo studies of pulmonary surfactant.

Market Dynamics

Increasing rate of prevalence of several respiratory infection and respiratory is expected to drive the global pulmonary surfactant market over the forecast period. For instance, on May 20, 2022, 90% of COPD (Chronic obstructive pulmonary disease) deaths were reported globally, in those under 70 years of age occur in low- and middle-income countries (LMIC) such as India, Korea and Bangladesh. Chronic obstructive pulmonary disease (COPD) is one of the major cause of death worldwide, causing 3.23 million deaths in 2019.

Increasing drug approvals for novel therapeutic agents are some of the key factors driving the global pulmonary surfactant market growth. For instance, in July 2020, Boehringer Ingelheim, a pharmaceutical company, announced that the European Commission (EC) approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF). The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020. The U.S. Food and Drug Administration (FDA), Health Canada and the Japan based pharmaceuticals and Medical Devices Agency (PMDA) approved nintedanib as the treatment for the same patient population. The approval is based on the results of INBUILD, which was a randomized, double-blind, placebo-controlled, parallel-group phase III trial, which evaluated the efficacy, safety, and tolerability of nintedanib in patients with chronic fibrosing ILDs with a progressive phenotype.

Key features of the study

This report provides an in-depth analysis of the global pulmonary surfactant market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global pulmonary surfactant market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include, Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pulmonary surfactant market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pulmonary surfactant

Market Segmentation

By Type
- Synthetic Pulmonary Surfactant
- Animal Derived Surfactant
By Drug Type
- Poractant alfa
- Lucinactant
- Calfactant
By Indications
- Respiratory Distress Syndrome (RDS)
- Respiratory Infections
- Obstructive lung Diseases
- Others (chronic lung disease of prematurity, and surfactant protein-B deficiency)
By Route of Administration
- Intratracheal
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Boehinger Ingelheim
- AbbVie Inc
- Chiesi Farmaceutici
- ONY Biotech Inc.
- Lyomark Pharma
- Abbott
- Aviva Systems Biology Corporation
- Windtree Therapeutics, Inc
- Tekzima (Noargen)
- Biomatik
- Nanjing Norris Pharm Technology
- Reddot Biotech

Product Code: CMI5324

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Indications
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Industry Trend
New Product Approvals/Launch
Merger and Acquisitions
PEST Analysis

4. Global Pulmonary Surfactant Market, By Type, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Synthetic Pulmonary Surfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Animal Derived Surfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

5. Global Pulmonary Surfactant Market, By Drug Type, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Poractant alfa
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Lucinactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Calfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

6. Global Pulmonary Surfactant Market, By Indications, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Respiratory Distress Syndrome (RDS)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Respiratory Infections
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Obstructive lung Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

7. Global Pulmonary Surfactant Market, By Route of Administration, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Intratracheal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

8. Global Pulmonary Surfactant Market, By Distribution Channel, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

9. Global Pulmonary Surfactant Market, By Region, 2026 - 2033, (USD Million)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - UK
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Heat Map Analysis
Company Profile
- Boehringer Ingelheim
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- AbbVie Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- Chiesi Farmaceutici
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- ONY Biotech Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- Lyomark Pharma
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- Abbott
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- Aviva Systems Biology Corporation
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- Windtree Therapeutics, Inc
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- Tekzima (Noargen)
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- Biomatik
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- Nanjing Norris Pharm Technology
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
- Reddot Biotech
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Analyst Views

11. Section

References
Research Methodology
About Us